Developer docs
API playgroundTry for free, no card

Search company profiles

Expert Systems, Inc

Full company profile

uuid004e6je

Namestring
Expert Systems, Inc
Legal namestring
Expert Systems, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Expert Systems, Inc. is a privately held Delaware-incorporated life sciences accelerator founded in 2019 that operates the Discover Medicines Hybrid AI Platform, an end-to-end Human-AI hybrid system covering preclinical drug discovery from target identification through virtual screening, ADMET prediction, chemical liability assessment, and in vitro toxicology. The stack comprises four named proprietary tools: TTRENDS (biotarget search), TargetGraph (knowledge base and KGML models for target-phenotype relationships), DrugInteLLM (LLM-based biomedical data access), and DiscoverNet (SMILES-based ML models for bioactivity and ADMET properties). The company is led by CEO Tudor I. Oprea, MD, PhD, with CTO Alexei Pushechnikov, PhD, CBO Bill Farley, and General Counsel Eddie Rodriguez, JD, supported by a scientific advisory board spanning UCSD, University of Tuebingen, DZNE, and University of Cincinnati.

The business model is accelerator-based rather than traditional SaaS: Expert Systems organizes and manages R&D programs with financial investors and strategic partners, incubates and owns equity stakes in seed and Series A portfolio companies, and earns service fees for drug discovery expertise. Portfolio companies include NeurOdys Therapeutics (Amsterdam, neurodegenerative), Mair Therapeutics (Nijmegen, Parkinson's), Mondego Bio (Cantanhede, PTPN2 immuno-oncology), Polku Therapeutics (Helsinki, neurodegenerative), BIMINI Biotech (Leiden, hematologic cancers), and jointly controlled ventures including Eilean Therapeutics, Lomond Therapeutics, and Trawsfynydd Therapeutics (Traws Pharma). The company reports 30+ R&D programs organized across North America, Europe, and Australia. Distribution is primarily direct accelerator partnerships with biotech/pharma, supplemented by strategic technology integrations such as the December 2025 collaboration with Quantori, which embeds Expert Systems' AI models as Q-Models into Quantori's Q-Scientist platform for enterprise pharma clients. No public pricing is disclosed; engagement is quote-based. The firm has 7 employees (headcount as of available data), with company headquarters registered at 8 The Green, Suite 8390, Dover, Delaware.

Short descriptiontext

Expert Systems is a 7-person life sciences accelerator that uses its proprietary Discover Medicines Hybrid AI Platform to incubate and co-develop seed and Series A biotech companies in oncology, neurodegenerative disease, and infectious disease therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDover, United States
HQ citystring
Dover
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, preclinical drug development, life sciences accelerator, computer-aided drug design, AI-powered therapeutics
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
AI-enabled Drug Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Accelerator Platform Services
TypeManaged Services
Description

Expert Systems operates as an advanced accelerator platform providing AI-enabled drug discovery services. The company generates revenue by organizing and managing R&D programs for financial investors and strategic partners, establishing seed and Series A companies. Revenue comes from equity stakes in incubated companies and service fees for drug development expertise.

expertsystems.inc
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1Discover Medicines Hybrid AI Platform
Description

End-to-end Human-AI hybrid platform for drug discovery and development covering preclinical stages from target identification to virtual screening.

expertsystems.inc
+5 more records
Core offering1 text field

Expert Systems operates a life sciences accelerator that provides AI-enabled drug discovery services through its Discover Medicines Hybrid AI Platform. The company combines proprietary experimental data with artificial intelligence and human expertise to support preclinical drug discovery from target identification through virtual screening, candidate selection, and preparation for first-in-human trials. It organizes and manages R&D programs and establishes seed and Series A biotech ventures in partnership with financial investors and strategic partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30+ R&D programs organized and managed across financial investors and strategic partners
+2 more records
Product overview1 text field

Expert Systems operates a life sciences accelerator offering the Discover Medicines Hybrid AI Platform, an end-to-end Human-AI hybrid system for drug discovery and development. The platform integrates multiple AI-powered tools including TTRENDS for biotarget searching, TargetGraph for knowledge base and target phenotype relationships, DrugInteLLM for LLM-based biomedical data access, and DiscoverNet for SMILES-based ML models for bioactivity and ADMET predictions. The comprehensive suite covers all aspects of preclinical drug discovery from target identification and virtual screening to pharmacokinetics, off-target pharmacology, chemical liability assessment, and in vitro toxicology. The company has established a portfolio of spin-off companies including Mondego Bio (PTPN2 inhibitors for immuno-oncology), NeurOdys Therapeutics (small molecules for neurodegenerative diseases), Mair Therapeutics (TMEM175 modulators for Parkinson's), BIMINI Biotech (WASp modulators for hematological cancers), and Polku Therapeutics (neurodegenerative disease treatments). Expert Systems also supports partner companies including Eilean Therapeutics (eiletoclax, lomonitinib, balamenib), Trawsfynydd Therapeutics (ratutrelvir/TRX01), and Lomond Therapeutics (lonitoclax).

Product and service5 records
1Discover Medicines Hybrid AI Platform
CategoryAI Drug Discovery Platform
Description

End-to-end Human-AI hybrid platform covering all aspects of preclinical drug discovery and early development phases, from target identification and virtual screening through non-clinical and clinical pharmacology, chemical liability assessment, and toxicology evaluation. Targeted at pharmaceutical companies and biotech firms requiring AI-enabled preclinical drug discovery services.

2Expert Systems Accelerator
CategoryDrug Discovery Accelerator Service
Description

Life sciences accelerator service that deploys Expert Systems' hybrid AI/ML technology to cover the entire spectrum of preclinical drug discovery and early development. Supports setup of seed and Series A companies and organizes R&D programs with financial investors and strategic partners across North America, Europe, and Australia.

3TTRENDS
CategoryTarget Identification Tool
Description

Standalone system for searching prospective biotargets, enabling identification and selection of therapeutic targets for drug discovery. Accessible via its own URL.

4DrugInteLLM
CategoryLLM-based Biomedical Data Tool
Description

Standalone suite of LLM-based tools that provides natural language access to biomedical data, databases, and ML models for drug discovery researchers. Accessible via its own URL.

5DiscoverNet
CategoryMolecular Property Prediction Tool
Description

Standalone suite of SMILES-based ML models for prediction of bioactivity, off-target effects, subcellular location, and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of drug candidates. Accessible via its own URL.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-15
Description

Strategic collaboration to integrate Expert Systems' novel AI models as Q-Models directly into Quantori's Q-Scientist platform. This integration equips pharmaceutical and biotech clients with capabilities to forecast critical outcomes, accelerate candidate selection, and optimize complex drug development workflows, substantially reducing time and cost associated with bringing new medicines to market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Swiss-based venture studio and part of Expert Systems accelerator platform. Rambam AG's diversified portfolio of companies and programs is supported by a core group of seasoned industrial experts, key opinion leaders, and dedicated functional experts from Switzerland, Netherlands, Portugal, Germany, and the US.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cutting-edge biopharmaceutical company established through collaboration between Orbimed, Torrey Pines Investment, and Dr. John C. Byrd. Harnesses Expert Systems' hybrid AI platform alongside exclusive data, chem-bio platforms, knowledge, and expertise to identify best-in-class and first-in-class small molecule inhibitors for cancer therapy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration partner for development of lonitoclax, a selective BCL-2 inhibitor. Expert Systems' cutting-edge AI-driven platform has been instrumental in preclinical efforts, speeding up identification and selection of lonitoclax through advanced computational modeling and comprehensive off-target pharmacology evaluations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing collaboration for development of Ratutrelvir (TRX01), a next-generation oral antiviral for COVID-19. Expert Systems' predictive pharmacology and AI-driven molecular modeling played a central role in optimizing pharmacokinetics, safety, and potency profiles without requiring ritonavir co-administration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Helsinki-based startup focused on developing treatments for neurodegenerative diseases. Expert Systems provides advanced computational tools and expertise to support Polku's drug discovery efforts in identifying therapeutic targets and optimizing candidate selection.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Accelerator partner listed on Expert Systems website as part of their partner ecosystem.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner in Expert Systems' global partner network for drug discovery services.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner in Expert Systems' global partner network, focusing on antiviral and infectious disease therapeutics.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ML-driven drug discovery platform combining induced pluripotent stem cell biology with predictive models for target and candidate discovery in neuroscience, oncology and metabolic disease.

TypeDirect peer
Description

Public computational drug discovery platform (physics-based + ML) covering target ID, virtual screening and ADMET. Closest direct competitor to Expert Systems' Discover Medicines platform with substantially larger scale.

TypeDirect peer
Description

AI-focused small-molecule discovery company using AtomNet convolutional neural networks for virtual screening and hit optimization, often via pharma partnerships similar to Expert Systems' accelerator model.

TypeDirect peer
Description

AI-driven small-molecule drug design company using generative chemistry and automated design; operates a Centaur AI platform analogous in scope to Expert Systems' Discover Medicines Hybrid AI Platform.

5Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company applying DeepMind-derived models (AlphaFold) to pharmaceutical discovery, including pharma partnerships; competing in the same end-to-end AI/ML discovery category.

TypeDirect peer
Description

AI-driven drug discovery company using knowledge graphs and ML for target identification, with an internal and partnered pipeline; comparable in leveraging biomedical data and AI for hypothesis generation.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with ML to advance an internal pipeline and partnerships; comparable in using AI/ML to compress preclinical timelines across multiple therapeutic areas.

8Iambic Therapeutics
TypeEmerging player
Description

AI-driven small-molecule drug discovery company combining physics-based simulation with neural networks for oncology candidates; comparable in scope but smaller stage with overlapping target prediction use case.

TypeDirect peer
Description

AI + robotics drug discovery platform combining quantum physics, ML and automated lab workflows for small-molecule discovery; directly competitive in AI-enabled lead design and ADMET prediction.

TypeEmerging player
Description

Computational biology platform offering protein structure prediction (Rosetta-based) and AI protein engineering services to pharma; overlaps with Expert Systems' computational model offerings and protein/biologic discovery.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Expert Systems, Inc

AI-enabled Drug Discovery Platformexpertsystems.inc

Expert Systems is a 7-person life sciences accelerator that uses its proprietary Discover Medicines Hybrid AI Platform to incubate and co-develop seed and Series A biotech companies in oncology, neurodegenerative disease, and infectious disease therapeutics.

What Expert Systems, Inc does

Expert Systems, Inc. is a privately held Delaware-incorporated life sciences accelerator founded in 2019 that operates the Discover Medicines Hybrid AI Platform, an end-to-end Human-AI hybrid system covering preclinical drug discovery from target identification through virtual screening, ADMET prediction, chemical liability assessment, and in vitro toxicology. The stack comprises four named proprietary tools: TTRENDS (biotarget search), TargetGraph (knowledge base and KGML models for target-phenotype relationships), DrugInteLLM (LLM-based biomedical data access), and DiscoverNet (SMILES-based ML models for bioactivity and ADMET properties). The company is led by CEO Tudor I. Oprea, MD, PhD, with CTO Alexei Pushechnikov, PhD, CBO Bill Farley, and General Counsel Eddie Rodriguez, JD, supported by a scientific advisory board spanning UCSD, University of Tuebingen, DZNE, and University of Cincinnati.

The business model is accelerator-based rather than traditional SaaS: Expert Systems organizes and manages R&D programs with financial investors and strategic partners, incubates and owns equity stakes in seed and Series A portfolio companies, and earns service fees for drug discovery expertise. Portfolio companies include NeurOdys Therapeutics (Amsterdam, neurodegenerative), Mair Therapeutics (Nijmegen, Parkinson's), Mondego Bio (Cantanhede, PTPN2 immuno-oncology), Polku Therapeutics (Helsinki, neurodegenerative), BIMINI Biotech (Leiden, hematologic cancers), and jointly controlled ventures including Eilean Therapeutics, Lomond Therapeutics, and Trawsfynydd Therapeutics (Traws Pharma). The company reports 30+ R&D programs organized across North America, Europe, and Australia. Distribution is primarily direct accelerator partnerships with biotech/pharma, supplemented by strategic technology integrations such as the December 2025 collaboration with Quantori, which embeds Expert Systems' AI models as Q-Models into Quantori's Q-Scientist platform for enterprise pharma clients. No public pricing is disclosed; engagement is quote-based. The firm has 7 employees (headcount as of available data), with company headquarters registered at 8 The Green, Suite 8390, Dover, Delaware.

Expert Systems, Inc firmographics

Firmographics
Name
Expert Systems, Inc
Legal name
Expert Systems, Inc.
Website
https://expertsystems.inc
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Expert Systems is a 7-person life sciences accelerator that uses its proprietary Discover Medicines Hybrid AI Platform to incubate and co-develop seed and Series A biotech companies in oncology, neurodegenerative disease, and infectious disease therapeutics.
Ownership category
akta.pro rank

Expert Systems, Inc industry classification

Industry
Product category
AI-enabled Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Scientific Research and Development Services (5417)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Preclinical drug development
  • Life sciences accelerator
  • Computer-aided drug design
  • AI-powered therapeutics

Where Expert Systems, Inc is headquartered

Location

Headquarters

HQ city
Dover
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Expert Systems, Inc business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Accelerator Platform Services: Expert Systems operates as an advanced accelerator platform providing AI-enabled drug discovery services. The company generates revenue by organizing and managing R&D programs for financial investors and strategic partners, establishing seed and Series A companies. Revenue comes from equity stakes in incubated companies and service fees for drug development expertise.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Expert Systems, Inc product offering

Product offering

Core offering

Expert Systems operates a life sciences accelerator that provides AI-enabled drug discovery services through its Discover Medicines Hybrid AI Platform. The company combines proprietary experimental data with artificial intelligence and human expertise to support preclinical drug discovery from target identification through virtual screening, candidate selection, and preparation for first-in-human trials. It organizes and manages R&D programs and establishes seed and Series A biotech ventures in partnership with financial investors and strategic partners.

Product overview

Expert Systems operates a life sciences accelerator offering the Discover Medicines Hybrid AI Platform, an end-to-end Human-AI hybrid system for drug discovery and development. The platform integrates multiple AI-powered tools including TTRENDS for biotarget searching, TargetGraph for knowledge base and target phenotype relationships, DrugInteLLM for LLM-based biomedical data access, and DiscoverNet for SMILES-based ML models for bioactivity and ADMET predictions. The comprehensive suite covers all aspects of preclinical drug discovery from target identification and virtual screening to pharmacokinetics, off-target pharmacology, chemical liability assessment, and in vitro toxicology. The company has established a portfolio of spin-off companies including Mondego Bio (PTPN2 inhibitors for immuno-oncology), NeurOdys Therapeutics (small molecules for neurodegenerative diseases), Mair Therapeutics (TMEM175 modulators for Parkinson's), BIMINI Biotech (WASp modulators for hematological cancers), and Polku Therapeutics (neurodegenerative disease treatments). Expert Systems also supports partner companies including Eilean Therapeutics (eiletoclax, lomonitinib, balamenib), Trawsfynydd Therapeutics (ratutrelvir/TRX01), and Lomond Therapeutics (lonitoclax).

Differentiator

Problem solved

Functional benefit

Brands

  • Discover Medicines Hybrid AI Platform: End-to-end Human-AI hybrid platform for drug discovery and development covering preclinical stages from target identification to virtual screening.
  • TTRENDS
  • TargetGraph
  • DrugInteLLM
  • DiscoverNet
  • Expert Systems Accelerator

Products and services

  • Discover Medicines Hybrid AI Platform End-to-end Human-AI hybrid platform covering all aspects of preclinical drug discovery and early development phases, from target identification and virtual screening through non-clinical and clinical pharmacology, chemical liability assessment, and toxicology evaluation. Targeted at pharmaceutical companies and biotech firms requiring AI-enabled preclinical drug discovery services.
  • Expert Systems Accelerator Life sciences accelerator service that deploys Expert Systems' hybrid AI/ML technology to cover the entire spectrum of preclinical drug discovery and early development. Supports setup of seed and Series A companies and organizes R&D programs with financial investors and strategic partners across North America, Europe, and Australia.
  • TTRENDS Standalone system for searching prospective biotargets, enabling identification and selection of therapeutic targets for drug discovery. Accessible via its own URL.
  • DrugInteLLM Standalone suite of LLM-based tools that provides natural language access to biomedical data, databases, and ML models for drug discovery researchers. Accessible via its own URL.
  • DiscoverNet Standalone suite of SMILES-based ML models for prediction of bioactivity, off-target effects, subcellular location, and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of drug candidates. Accessible via its own URL.

Quantifiable outcome

  • 30+ R&D programs organized and managed across financial investors and strategic partners
  • +2 more outcomes

Companies that use Expert Systems, Inc

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Expert Systems, Inc technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Expert Systems, Inc partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • QuantoricoreTechnology or Integration · 15 December 2025Strategic collaboration to integrate Expert Systems' novel AI models as Q-Models directly into Quantori's Q-Scientist platform. This integration equips pharmaceutical and biotech clients with capabilities to forecast critical outcomes, accelerate candidate selection, and optimize complex drug development workflows, substantially reducing time and cost associated with bringing new medicines to market.
  • Rambam AGcoreStrategic or Co-development PartnerSwiss-based venture studio and part of Expert Systems accelerator platform. Rambam AG's diversified portfolio of companies and programs is supported by a core group of seasoned industrial experts, key opinion leaders, and dedicated functional experts from Switzerland, Netherlands, Portugal, Germany, and the US.
  • Eilean TherapeuticscoreStrategic or Co-development PartnerCutting-edge biopharmaceutical company established through collaboration between Orbimed, Torrey Pines Investment, and Dr. John C. Byrd. Harnesses Expert Systems' hybrid AI platform alongside exclusive data, chem-bio platforms, knowledge, and expertise to identify best-in-class and first-in-class small molecule inhibitors for cancer therapy.
  • Lomond TherapeuticscoreStrategic or Co-development PartnerCollaboration partner for development of lonitoclax, a selective BCL-2 inhibitor. Expert Systems' cutting-edge AI-driven platform has been instrumental in preclinical efforts, speeding up identification and selection of lonitoclax through advanced computational modeling and comprehensive off-target pharmacology evaluations.
  • Traws Pharma (Trawsfynydd Therapeutics)coreStrategic or Co-development PartnerOngoing collaboration for development of Ratutrelvir (TRX01), a next-generation oral antiviral for COVID-19. Expert Systems' predictive pharmacology and AI-driven molecular modeling played a central role in optimizing pharmacokinetics, safety, and potency profiles without requiring ritonavir co-administration.
  • Polku TherapeuticsminorStrategic or Co-development PartnerHelsinki-based startup focused on developing treatments for neurodegenerative diseases. Expert Systems provides advanced computational tools and expertise to support Polku's drug discovery efforts in identifying therapeutic targets and optimizing candidate selection.
  • i2020 AcceleratorminorChannel Partner/ Reseller/ DistributorAccelerator partner listed on Expert Systems website as part of their partner ecosystem.
  • ChemDivminorStrategic or Co-development PartnerListed as a partner in Expert Systems' global partner network for drug discovery services.
  • ViriomminorStrategic or Co-development PartnerListed as a partner in Expert Systems' global partner network, focusing on antiviral and infectious disease therapeutics.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Expert Systems, Inc competitors and assessment

Company assessment

Direct peers

  • Insitro: ML-driven drug discovery platform combining induced pluripotent stem cell biology with predictive models for target and candidate discovery in neuroscience, oncology and metabolic disease.
  • Schrödinger, Inc. Public computational drug discovery platform (physics-based + ML) covering target ID, virtual screening and ADMET. Closest direct competitor to Expert Systems' Discover Medicines platform with substantially larger scale.
  • Atomwise: AI-focused small-molecule discovery company using AtomNet convolutional neural networks for virtual screening and hit optimization, often via pharma partnerships similar to Expert Systems' accelerator model.
  • Exscientia (merged with Recursion): AI-driven small-molecule drug design company using generative chemistry and automated design; operates a Centaur AI platform analogous in scope to Expert Systems' Discover Medicines Hybrid AI Platform.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company applying DeepMind-derived models (AlphaFold) to pharmaceutical discovery, including pharma partnerships; competing in the same end-to-end AI/ML discovery category.
  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML for target identification, with an internal and partnered pipeline; comparable in leveraging biomedical data and AI for hypothesis generation.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML to advance an internal pipeline and partnerships; comparable in using AI/ML to compress preclinical timelines across multiple therapeutic areas.
  • XtalPi: AI + robotics drug discovery platform combining quantum physics, ML and automated lab workflows for small-molecule discovery; directly competitive in AI-enabled lead design and ADMET prediction.

Emerging players

  • Iambic Therapeutics: AI-driven small-molecule drug discovery company combining physics-based simulation with neural networks for oncology candidates; comparable in scope but smaller stage with overlapping target prediction use case.
  • Cyrus Biotechnology: Computational biology platform offering protein structure prediction (Rosetta-based) and AI protein engineering services to pharma; overlaps with Expert Systems' computational model offerings and protein/biologic discovery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Expert Systems, Inc social profiles

Digital presence

Expert Systems, Inc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Expert Systems, Inc leadership team

Management profile

Number of profiles

Profiles10 records

Expert Systems, Inc subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Expert Systems, Inc funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Expert Systems, Inc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Expert Systems, Inc

What does Expert Systems, Inc do?

Expert Systems operates a life sciences accelerator that provides AI-enabled drug discovery services through its Discover Medicines Hybrid AI Platform. The company combines proprietary experimental data with artificial intelligence and human expertise to support preclinical drug discovery from target identification through virtual screening, candidate selection, and preparation for first-in-human trials. It organizes and manages R&D programs and establishes seed and Series A biotech ventures in partnership with financial investors and strategic partners.

Is Expert Systems, Inc a public or private company?

Expert Systems, Inc is a private company. It is classified as venture growth investor backed and is currently operating.

When was Expert Systems, Inc founded?

Expert Systems, Inc was founded in 2019. It employs 11 to 50 people.

Where is Expert Systems, Inc based?

Expert Systems, Inc is headquartered in Dover, United States, in the North America region.

How does Expert Systems, Inc make money?

One revenue line is on record: accelerator Platform Services.

Who are Expert Systems, Inc's main competitors?

Direct peers on record are Insitro, Schrödinger, Inc., Atomwise, Exscientia (merged with Recursion), Isomorphic Labs, BenevolentAI, Recursion Pharmaceuticals and XtalPi. Emerging players are Iambic Therapeutics and Cyrus Biotechnology.

Does Expert Systems, Inc have an API?

No public API is recorded for Expert Systems, Inc.

What industry is Expert Systems, Inc in?

Expert Systems, Inc's product category is AI-enabled Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceMwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.Mwyngil Therapeutics Inc. announced it has licensed GPR75 modulator molecules and a cell-surface discovery platform from Expert Systems Inc. to advance treatments for obesity, T2D, and inflammatory diseases, strengthening its portfolio in cardiometabolic and chronic inflammatory indications. The partnership aims to develop novel therapies leveraging GPR75 and NLRP3 inhibitors for metabolic and cardiovascular health.PR NewswireDover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.Expert Systems Inc., a life sciences accelerator, announced continued support for Traws Pharma as it initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a ritonavir-free oral antiviral for COVID-19. In Phase 1 studies, a 600mg daily regimen maintained plasma concentrations approximately 13 times above EC50 over 10 days, with regulatory approval for Phase 2 granted in Q3 2025. The Phase 2 program includes a non-inferiority trial against PAXLOVID and a separate trial in PAXLOVID-ineligible populations, an underserved group currently excluded from protease inhibitor treatments.PR NewswireExpert Systems Inc., a leading drug discovery accelerator, proudly announces the Series A funding and launch of Mondego Bio, an emerging immuno-oncology company headquartered at Biocant Park in CantanExpert Systems Inc. announced the launch of Mondego Bio, an immuno-oncology company, following Series A funding. Mondego Bio is developing PTPN2 inhibitors to enhance cancer immunotherapy, using AI/ML-driven drug design supported by Expert Systems.YahooExpert Systems Inc., a leading drug discovery accelerator, proudly announces the Series A funding and launch of Mondego Bio, an emerging immuno-oncology company headquartered at Biocant Park in CantanExpert Systems Inc. announced Series A funding and the launch of Mondego Bio, an immuno-oncology company, backed by Biovance Capital, Torrey Pines Investment, and OrbiMed. Mondego Bio is advancing a portfolio of PTPN2 inhibitors for cancer immunotherapy, with Expert Systems providing ongoing support as the company moves toward first-in-human studies.TmcnetExpert Systems Expands Operations in Europe to Support Drug Discovery for Neurodegenerative Diseases with Polku TherapeuticsExpert Systems is expanding in Europe through a collaboration with Polku Therapeutics, a Helsinki-based startup developing treatments for Parkinson's and Alzheimer's diseases. Expert Systems will provide AI-driven computational tools to support Polku's drug discovery, including target identification and candidate optimization. The partnership aims to de-risk and accelerate Polku's development programs.YahooExpert Systems Expands Operations in Europe to Support Drug Discovery for Neurodegenerative Diseases with Polku TherapeuticsExpert Systems is expanding in Europe through a collaboration with Polku Therapeutics, a Helsinki-based startup developing treatments for Parkinson's and Alzheimer's disease. Expert Systems will provide AI-driven computational tools to support Polku's drug discovery, aiming to de-risk and accelerate candidate selection. The partnership is part of Expert Systems' strategy to apply its platform to high-impact research areas.Business & FinancialExpert Systems Expands Operations In Europe To Support Drug Discovery For Neurodegenerative Diseases With Polku TherapeuticsExpert Systems is expanding its European operations through a collaboration with Polku Therapeutics, a Helsinki-based startup developing treatments for Parkinson's and Alzheimer's disease. Expert Systems will provide AI-driven computational tools to support Polku's drug discovery, including target identification and candidate optimization. The partnership aims to accelerate early-stage drug discovery in neuroscience.